PfSPZ Vaccine learns a lesson

Irfan Zaidi; Patrick E Duffy

doi:10.1016/j.medj.2021.11.002

PfSPZ Vaccine learns a lesson

Med. 2021 Dec 10;2(12):1289-1291. doi: 10.1016/j.medj.2021.11.002.

Authors

Irfan Zaidi¹, Patrick E Duffy²

Affiliations

¹ Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD USA.
² Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD USA. Electronic address: patrick.duffy@nih.gov.

Abstract

In Kenya, the first trial of the attenuated whole organism PfSPZ Vaccine in infants has shown little efficacy against malaria infection, whereas trials in African adults have repeatedly observed protection. Differences in immune responses offer clues to the possible reasons.

Published by Elsevier Inc.

Publication types

Research Support, N.I.H., Intramural
Comment

MeSH terms

Adult
Clinical Trials as Topic
Humans
Infant
Malaria Vaccines* / therapeutic use
Malaria* / prevention & control
Vaccine Efficacy
Vaccines, Attenuated / therapeutic use

Substances

Malaria Vaccines
Vaccines, Attenuated